HIV Clinical Trials Market to Grow with a CAGR of 6.90% through 2028

Scientific progress, international cooperation, and increased funding are expected to drive the Global HIV Clinical Trials Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “HIV Clinical Trials Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global HIV Clinical Trials Market stood at USD 1.23 billion in 2022 and is anticipated to grow with a CAGR of 6.90% in the forecast period, 2024-2028. This can be attributed to patient engagement. Patients and advocacy groups have become actively involved in shaping the HIV clinical trial landscape. Their contributions range from participating in trials to advocating for more patient-centric research and demanding the inclusion of diverse populations. This patient engagement helps ensure that clinical trials are relevant and accessible. Moreover, advanced data analytics and artificial intelligence are being harnessed to analyze large datasets generated by HIV clinical trials. These technologies can uncover insights, identify trends, and facilitate more efficient trial designs.

Market expansion can be attributed to several factors, including heightened research and development investments in HIV clinical trials by pharmaceutical and biotechnology firms, an upsurge in approvals for HIV medications, and a growing incidence of HIV within the population. Nevertheless, this growth was impeded by the COVID-19 pandemic, which resulted in a sudden surge in pandemic-related trials, slowing down trial enrollment and causing a shift in focus to COVID-19 drug research. Government-imposed stay-at-home orders during the pandemic disrupted HIV testing and diagnosis, resulting in a significant decrease in referrals and treatment for HIV and AIDS. However, starting in 2021, the increasing prevalence of HIV among individuals unable to seek treatment due to stay-at-home measures will create a substantial patient pool, spurring the development of new methods for HIV infection prevention and consequently driving market growth. A multitude of non-profit organizations, alongside pharmaceutical and biotechnology companies, are funneling investments into the HIV clinical research sector for therapeutic treatments. For instance, in April 2021, non-profit organizations IAVI and Scripps Research announced the completion of a phase I clinical trial for a groundbreaking HIV vaccine. Additionally, Excision revealed that the FDA had granted approval for its Investigational New Drug (IND) to treat chronic HIV, known as EBT-101.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global HIV Clinical Trials Market.”

Significant advancements in HIV drug development have emerged in recent years, thanks to the increased expenditure in HIV drug research and development. An illustrative example is ViiV Healthcare's announcement in December 2021 regarding the FDA-approved treatment Apretude, designed to prevent sexually acquired HIV-1 infection. Apretude is a long-acting injectable pre-exposure prophylaxis (PrEP) employed in HIV disease management. The Global HIV Clinical Trials Market is segmented into phase, study design, sponsor, regional distribution, and company. Based on its phase, Phase I dominated the revenue share in 2022 and is also projected to exhibit the highest Compound Annual Growth Rate (CAGR) during the forecast period. Phase I studies primarily focus on evaluating the safety of HIV drugs, assessing their tolerability, and examining their pharmacokinetics in human subjects. These studies investigate how HIV drugs are absorbed, metabolized, and eliminated in the body, as well as potential side effects when dosage levels are increased. Typically, Phase I involves a cohort of 20 to 100 participants, including both healthy volunteers and individuals with the disease.

On the other hand, Phase II is expected to achieve the second highest CAGR during the forecast period. This is attributed to increased investments in HIV clinical trial research and development by both industry and non-industry sponsors. Factors driving this growth include the rising number of industry-sponsored and non-industry-sponsored clinical trials in Phase II, the inherent complexity of Phase II clinical trials, and the global expansion of clinical trial activities. Based on study design, The interventional studies category claimed the largest share of revenue in 2022, and it is projected to achieve the second highest CAGR during the forecast period. These interventional studies play a pivotal role in identifying cost-effective, scalable, and preventive strategies for addressing HIV infection. They also serve to evaluate the strengths and weaknesses of a trial, gauge the treatment's impact on individuals, and mitigate limitations at the outset.

Conversely, the expanded access studies sector is poised to experience the most rapid CAGR over the forecast period. This surge can be primarily attributed to ongoing innovations in HIV treatment. Expanded access represents an important approach for patients dealing with severe, life-threatening HIV conditions. In this context, patients are granted access to treatment outside of a clinical trial if the trial results prove unsatisfactory or fail to demonstrate any improvement.

Major companies operating in Global HIV Clinical Trials Market are:

• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• Syneos Health Inc
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global HIV Clinical Trials Market is on the cusp of significant advancements, driven by the emerging trends. As researchers and stakeholders continue to innovate and collaborate, breakthroughs in treatment, prevention, and the pursuit of a cure for HIV can be anticipated. These developments offer hope for a future where HIV/AIDS is no longer a global health crisis. However, it is important to acknowledge that challenges, including resource constraints and regulatory complexities, must also be addressed to ensure these trends translate into tangible benefits for those affected by HIV/AIDS,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“HIV Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor (Pharmaceutical & Biopharmaceutical Companies, Non-Profit Organizations, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global HIV Clinical Trials Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global HIV Clinical Trials Market.

Contact

Mr. Ken Mathews

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com